CYSLTR1 and COVID-19: The established relaxant effects of CHA-12 on pulmonary smooth muscles through antagonistic activity on CysLT1, which was reported previously by in vivo and in vitro assessments, along with our predictions of its amazing effects on all virus and host-based targets promise the introduction of a valuable compound for the treatment of COVID-19.